If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback